niacinamide has been researched along with Multiple Primary Neoplasms in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies." | 7.83 | Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. ( Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P, 2016) |
| "A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 7.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
| "The prognosis for hepatocellular carcinoma (HCC) is dependent upon tumour stage, performance status (PS), severity of underlying liver disease, and the availability of appropriate therapies." | 5.39 | Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. ( Hargreaves, S; Hull, D; Hussain, SA; Johnson, PJ; Ma, YT; Palmer, DH; Ross, PJ; Smith, AJ, 2013) |
| "Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies." | 3.83 | Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. ( Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P, 2016) |
| "A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 3.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
| "The prognosis for hepatocellular carcinoma (HCC) is dependent upon tumour stage, performance status (PS), severity of underlying liver disease, and the availability of appropriate therapies." | 1.39 | Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. ( Hargreaves, S; Hull, D; Hussain, SA; Johnson, PJ; Ma, YT; Palmer, DH; Ross, PJ; Smith, AJ, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, F | 1 |
| Bian, S | 1 |
| Zhu, D | 1 |
| Yuan, Y | 1 |
| Pan, K | 1 |
| Pan, Z | 1 |
| Feng, X | 1 |
| Tang, K | 1 |
| Yang, Y | 1 |
| Palmer, DH | 1 |
| Hussain, SA | 1 |
| Smith, AJ | 1 |
| Hargreaves, S | 1 |
| Ma, YT | 1 |
| Hull, D | 1 |
| Johnson, PJ | 1 |
| Ross, PJ | 1 |
| Tan-Shalaby, J | 1 |
| Escudero-Góngora, MM | 1 |
| Fernández-Peñas, P | 1 |
| Casadei Gardini, A | 1 |
| Chiadini, E | 1 |
| Faloppi, L | 1 |
| Marisi, G | 1 |
| Delmonte, A | 1 |
| Scartozzi, M | 1 |
| Loretelli, C | 1 |
| Lucchesi, A | 1 |
| Oboldi, D | 1 |
| Dubini, A | 1 |
| Frassineti, GL | 1 |
| Ulivi, P | 1 |
| Bhullar, M | 1 |
| Bhullar, A | 1 |
| Arachchi, NJ | 1 |
| Schoental, R | 1 |
1 review available for niacinamide and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Nicotinamide: New Indications in Dermatology.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; Clinical Trials, Phase III as Topi | 2016 |
6 other studies available for niacinamide and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with
Topics: Fluorine Radioisotopes; Humans; Machine Learning; Male; Neoplasms, Multiple Primary; Niacinamide; Ol | 2022 |
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort | 2013 |
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fl | 2013 |
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Topics: Aged; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Liver Neoplasms; Lung Neopl | 2016 |
Painful Rashes on the Palms and Soles.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; | 2016 |
The role of nicotinamide and of certain other modifying factors in diethylnitrosamine carcinogenesis: fusaria mycotoxins and "spontaneous" tumors in animals and man.
Topics: Animals; Diethylnitrosamine; Female; Fusarium; Gastrointestinal Neoplasms; Genital Neoplasms, Female | 1977 |